Stay updated with breaking news from Vicore Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
STOCKHOLM, SE / ACCESSWIRE / May 31, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 31, 2024 - Vicore Pharma Holding AB (STO: VICO) ("Vicore") announced today that the number of Vicore shares and
STOCKHOLM, SWEDEN / ACCESSWIRE / May 20, 2024 / Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis reflected an increase in...
Both drugs have the potential to offer a disease-modifying approach to the lung disease
Vicore Pharma will initiate the Phase IIb trial by the end of H1 2024.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!